Risankizumab to treat moderately to severely active Crohn’s disease in adults: an evaluation of trials and data

IF 3.8 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Expert Review of Gastroenterology & Hepatology Pub Date : 2023-12-14 DOI:10.1080/17474124.2023.2295496

Amanda M. Johnson, Edward V. Loftus Jr.

引用次数: 0

Abstract

Risankizumab is a humanized monoclonal antibody that selectively inhibits interleukin (IL)-23. It is approved for the treatment of moderate-to-severe plaque psoriasis, psoriatic arthritis, and more...

查看原文本刊更多论文

利桑珠单抗治疗成人中度至重度活动性克罗恩病：试验和数据评估

利桑珠单抗是一种选择性抑制白细胞介素（IL）-23的人源化单克隆抗体。它已被批准用于治疗中重度斑块状银屑病、银屑病关节炎等。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Gastroenterology & Hepatology GASTROENTEROLOGY & HEPATOLOGY-

CiteScore

6.80

自引率

2.60%

发文量

审稿时长

6-12 weeks

期刊介绍： The enormous health and economic burden of gastrointestinal disease worldwide warrants a sharp focus on the etiology, epidemiology, prevention, diagnosis, treatment and development of new therapies. By the end of the last century we had seen enormous advances, both in technologies to visualize disease and in curative therapies in areas such as gastric ulcer, with the advent first of the H2-antagonists and then the proton pump inhibitors - clear examples of how advances in medicine can massively benefit the patient. Nevertheless, specialists face ongoing challenges from a wide array of diseases of diverse etiology.